RareCyte: Funding, Investors & Team (Sep 2026)
As a one-stop shop for Spatial Biology and Liquid Biopsy solutions, RareCyte is trusted by leaders in Research, Translational Medicine, and the Clinic. RareCyte is a cutting-edge precision biology firm with its headquarters in Seattle, Washington. It has created technologies and end-to-end integrated platforms that have enabled advancements in oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy. Through the use of rare cell analysis, our highly multiplexed fluorescence imaging equipment, reagents, and contract services enable researchers to reveal the spatial context of important biomarkers and develop therapies and companion diagnostics.
RareCyte has raised $24.0M across 2 funding rounds on record, the most recent an undisclosed round announced in Nov 2022.
RareCyte Company Profile and Key Stats
Latest funding round on record: Nov 2022.
RareCyte Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
RareCyte raised $24.0M in a Series G announced in Sep 2021.
1.2 years later, an undisclosed round was announced in Nov 2022 with no disclosed amount.
RareCyte Founders and Leadership Team
Contact details for the RareCyte team: 1 of 1 has an email address on file.
Start 14-day free trial →RareCyte Funding Compared to Other Biotechnology Startups
Funded Startups Like RareCyte in Biotechnology and Seattle
Companies Similar to RareCyte
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
RareCyte Funding FAQs
What does RareCyte do?
As a one-stop shop for Spatial Biology and Liquid Biopsy solutions, RareCyte is trusted by leaders in Research, Translational Medicine, and the Clinic. RareCyte is a cutting-edge precision biology firm with its headquarters in Seattle, Washington. It has created technologies and end-to-end integrated platforms that have enabled advancements in oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy. Through the use of rare cell analysis, our highly multiplexed fluorescence imaging equipment, reagents, and contract services enable researchers to reveal the spatial context of important biomarkers and develop therapies and companion diagnostics.
How much funding has RareCyte raised?
RareCyte has raised $24.0M across 2 rounds on record.
When did RareCyte last raise funding?
RareCyte's most recent funding round on record was announced in Nov 2022. The amount was not disclosed.
Who is the CEO of RareCyte?
Joseph Victor is listed as CEO at RareCyte.
Where is RareCyte headquartered?
RareCyte is based in Seattle, Washington, United States.
How many employees does RareCyte have?
RareCyte is in the 51-100 employee band.
About FundedIQ's RareCyte Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for RareCyte is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.